Cargando…
Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer
BACKGROUND: Circulating tumor cells (CTCs) represent a collection of heterogeneous cells. Studies have shown epithelial CTCs and folate receptor (FR) positive CTCs could be used as diagnostic biomarkers for lung cancer (LC). This study aimed to determine whether cell surface vimentin (CSV) positive...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162210/ https://www.ncbi.nlm.nih.gov/pubmed/34055642 http://dx.doi.org/10.3389/fonc.2021.672687 |
_version_ | 1783700663165779968 |
---|---|
author | Xie, Xiaohong Wang, Liqiang Wang, Xinni Fan, Wan-Hung Qin, Yinyin Lin, Xinqing Xie, Zhanhong Liu, Ming Ouyang, Ming Li, Shiyue Zhou, Chengzhi |
author_facet | Xie, Xiaohong Wang, Liqiang Wang, Xinni Fan, Wan-Hung Qin, Yinyin Lin, Xinqing Xie, Zhanhong Liu, Ming Ouyang, Ming Li, Shiyue Zhou, Chengzhi |
author_sort | Xie, Xiaohong |
collection | PubMed |
description | BACKGROUND: Circulating tumor cells (CTCs) represent a collection of heterogeneous cells. Studies have shown epithelial CTCs and folate receptor (FR) positive CTCs could be used as diagnostic biomarkers for lung cancer (LC). This study aimed to determine whether cell surface vimentin (CSV) positive CTCs could be used as a biomarker for LC as well. METHODS: 78 treatment-naïve non-small-cell lung cancer (NSCLC) patients, 21 patients with benign lung diseases (BLD) and 9 healthy donors (HD) were enrolled in this study. CTC detection was performed using CytoSorter(®) mesenchymal CTC kit (CSV). The correlation between CSV positive CTCs (CSV-CTCs) and LC patients’ clinicopathological characteristics would be evaluated, and diagnostic performances of CSV-CTCs and serum tumor markers for LC would be compared. RESULTS: CTC detection rates (average CTC count: range) in LC patients, patients with BLD and HD were 83.33% (2.47: 0-8), 47.62% (0.5: 0-3) and 0% (0: 0), respectively. CSV-CTCs could be used to differentiate LC patients from the patients with BLD and HD (P < 0.0001). CSV-CTCs were correlated with cancer stage, lymph node involvement and distant metastasis (P = 0.0062, 0.0014 and 0.0021, respectively). With a CTC cut-off value of 2, CSV-CTCs would have a sensitivity and specificity of 0.67 and 0.87, respectively, for diagnosing LC. CSV-CTC positive rates showed statistical differences among HD, BLD patients and LC patients at different cancer stages (P < 0.0001). Furthermore, CSV-CTC positive rates were positively correlated with tumor size, lymph node involvement and distant metastasis (P = 0.0163, 0.0196 and 0.03, respectively). CSV-CTCs had a better diagnostic performance than serum tumor makers, such as carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cancer antigen 125 (CA125) and CA153. CONCLUSION: When CTC cut-off is set to 2 CTCs per 7.5 mL of blood, CSV-CTCs can be considered as an acceptable biomarker for diagnosing LC with a sensitivity and specificity of 0.67 and 0.87, respectively. |
format | Online Article Text |
id | pubmed-8162210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81622102021-05-29 Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer Xie, Xiaohong Wang, Liqiang Wang, Xinni Fan, Wan-Hung Qin, Yinyin Lin, Xinqing Xie, Zhanhong Liu, Ming Ouyang, Ming Li, Shiyue Zhou, Chengzhi Front Oncol Oncology BACKGROUND: Circulating tumor cells (CTCs) represent a collection of heterogeneous cells. Studies have shown epithelial CTCs and folate receptor (FR) positive CTCs could be used as diagnostic biomarkers for lung cancer (LC). This study aimed to determine whether cell surface vimentin (CSV) positive CTCs could be used as a biomarker for LC as well. METHODS: 78 treatment-naïve non-small-cell lung cancer (NSCLC) patients, 21 patients with benign lung diseases (BLD) and 9 healthy donors (HD) were enrolled in this study. CTC detection was performed using CytoSorter(®) mesenchymal CTC kit (CSV). The correlation between CSV positive CTCs (CSV-CTCs) and LC patients’ clinicopathological characteristics would be evaluated, and diagnostic performances of CSV-CTCs and serum tumor markers for LC would be compared. RESULTS: CTC detection rates (average CTC count: range) in LC patients, patients with BLD and HD were 83.33% (2.47: 0-8), 47.62% (0.5: 0-3) and 0% (0: 0), respectively. CSV-CTCs could be used to differentiate LC patients from the patients with BLD and HD (P < 0.0001). CSV-CTCs were correlated with cancer stage, lymph node involvement and distant metastasis (P = 0.0062, 0.0014 and 0.0021, respectively). With a CTC cut-off value of 2, CSV-CTCs would have a sensitivity and specificity of 0.67 and 0.87, respectively, for diagnosing LC. CSV-CTC positive rates showed statistical differences among HD, BLD patients and LC patients at different cancer stages (P < 0.0001). Furthermore, CSV-CTC positive rates were positively correlated with tumor size, lymph node involvement and distant metastasis (P = 0.0163, 0.0196 and 0.03, respectively). CSV-CTCs had a better diagnostic performance than serum tumor makers, such as carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cancer antigen 125 (CA125) and CA153. CONCLUSION: When CTC cut-off is set to 2 CTCs per 7.5 mL of blood, CSV-CTCs can be considered as an acceptable biomarker for diagnosing LC with a sensitivity and specificity of 0.67 and 0.87, respectively. Frontiers Media S.A. 2021-05-14 /pmc/articles/PMC8162210/ /pubmed/34055642 http://dx.doi.org/10.3389/fonc.2021.672687 Text en Copyright © 2021 Xie, Wang, Wang, Fan, Qin, Lin, Xie, Liu, Ouyang, Li and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xie, Xiaohong Wang, Liqiang Wang, Xinni Fan, Wan-Hung Qin, Yinyin Lin, Xinqing Xie, Zhanhong Liu, Ming Ouyang, Ming Li, Shiyue Zhou, Chengzhi Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer |
title | Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer |
title_full | Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer |
title_fullStr | Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer |
title_full_unstemmed | Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer |
title_short | Evaluation of Cell Surface Vimentin Positive Circulating Tumor Cells as a Diagnostic Biomarker for Lung Cancer |
title_sort | evaluation of cell surface vimentin positive circulating tumor cells as a diagnostic biomarker for lung cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162210/ https://www.ncbi.nlm.nih.gov/pubmed/34055642 http://dx.doi.org/10.3389/fonc.2021.672687 |
work_keys_str_mv | AT xiexiaohong evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer AT wangliqiang evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer AT wangxinni evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer AT fanwanhung evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer AT qinyinyin evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer AT linxinqing evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer AT xiezhanhong evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer AT liuming evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer AT ouyangming evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer AT lishiyue evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer AT zhouchengzhi evaluationofcellsurfacevimentinpositivecirculatingtumorcellsasadiagnosticbiomarkerforlungcancer |